Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Bibliographic Details
Main Authors:	Weiwei Huang, Chenxi Wang, Yangkun Shen, Qi Chen, Zhijian Huang, Jian Liu, Xiaoyan Lin, Lili Wang, Fan Wu, Xinhua Chen, Nani Li, Yi Hong, Mulan Chen, Jieyu Li, Chuanzhong Huang
Format:	Article
Language:	English
Published:	BMC 2024-03-01
Series:	BMC Cancer
Online Access:	https://doi.org/10.1186/s12885-024-12150-8

Similar Items

A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
by: Weiwei Huang, et al.
Published: (2024-01-01)

Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
by: Weiwei Huang, et al.
Published: (2024-02-01)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01)

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
by: Mengru Cao, et al.
Published: (2023-05-01)

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
by: Dou-Dou Li, et al.
Published: (2022-09-01)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer
by: CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
Published: (2021-12-01)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
by: Zhaolun Cai, et al.
Published: (2019-06-01)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
by: Taojun Gong, et al.
Published: (2022-11-01)

Efficacy of neoadjuvant chemotherapy combined with low-dose Apatinib in the treatment of triple negative breast cancer
by: Jin-Zhe Yang, et al.
Published: (2023-07-01)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01)

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature
by: Bi J, et al.
Published: (2017-07-01)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
by: Jieqiong Liu, et al.
Published: (2022-05-01)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
by: Dingyi Jiang, et al.
Published: (2020-07-01)

A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
by: Tianyu Zeng, et al.
Published: (2022-08-01)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
by: Shuanghe Li, et al.
Published: (2022-10-01)

Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer
by: Yu-Hsiang Huang, et al.
Published: (2021-06-01)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
by: Jiaqiang Wang, et al.
Published: (2023-11-01)

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
by: Yaxin Liu, et al.
Published: (2023-09-01)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
by: Zhichao Liao, et al.
Published: (2019-02-01)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022-08-01)

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
by: Ciqiu Yang, et al.
Published: (2022-08-01)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
by: Xuelian Chen, et al.
Published: (2023-12-01)

Chondroitin Sulfate Targeting Nanodrug Achieves Near-Infrared Fluorescence-Guided Chemotherapy Against Triple-Negative Breast Primary and Lung Metastatic Cancer
by: Huang C, et al.
Published: (2022-11-01)

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
by: Anjie Zhu, et al.
Published: (2021-08-01)

Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
by: Zhongyu Wang, et al.
Published: (2021-07-01)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
by: Ya-Ya Deng, et al.
Published: (2023-04-01)

Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins
by: Yu-Dong Zhou, et al.
Published: (2018-11-01)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
by: Lingying Zhao, et al.
Published: (2022-05-01)

Therapy options for metastatic triple negative breast cancer
by: E. V. Glazkova, et al.
Published: (2022-06-01)

Opportunities for metastatic triple negative breast cancer therapy
by: Inna P. Ganshina, et al.
Published: (2021-05-01)

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
by: Yunyan Mo, et al.
Published: (2024-01-01)

Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study
by: Lulu Ye, et al.
Published: (2023-04-01)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021-05-01)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
by: Zhengbo Song, et al.
Published: (2022-05-01)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
by: Jigang Chen, et al.
Published: (2021-10-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01)

Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study
by: Chenchen Wang, et al.
Published: (2021-08-01)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
by: Jia-Yi Huang, et al.
Published: (2023-04-01)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
by: Huang Y, et al.
Published: (2023-07-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)